Miles/Onyx
Executive Summary
Five-year R&D collaboration announced May 3 will focus on cancer drugs developed from small molecules inhibiting the "ras intracellular signaling pathways," Richmond, Calif.-based Chiron spin-off Onyx Pharmaceuticals said. Miles will make a $13.5 mil. equity investment in privately held Onyx and provide $25 mil. in research funding. Miles will have worldwide development and marketing rights